Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Tufts Medical Center Eli Lilly and Company |
---|---|
Information provided by: | Tufts Medical Center |
ClinicalTrials.gov Identifier: | NCT00129974 |
The purpose of the study is to determine whether pemetrexed and gemcitabine cause good tumour shrinkage when given to patients with previously untreated extensive-stage small cell lung cancer. The second purpose is to see if the side effects appear better than what is expected with standard chemotherapy.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Small Cell |
Drug: pemetrexed and gemcitabine |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma |
Estimated Enrollment: | 46 |
Study Start Date: | August 2005 |
Extensive-stage small cell lung carcinoma is incurable. Present therapies are toxic and responses are short lived. This phase II, single arm, window of opportunity study will assess the response rate and toxicity of pemetrexed and gemcitabine in this cohort.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients must have normal organ and marrow function as defined below:
Exclusion Criteria:
United States, Massachusetts | |
Tufts-New England Medical Center | |
Boston, Massachusetts, United States, 02111 | |
Baystate Medical Center | |
Springfield, Massachusetts, United States, 01199 | |
Commonwealth Hematology/Oncology | |
Quincy, Massachusetts, United States, 02169 |
Principal Investigator: | John R Goffin, MD FRCPC | Tufts Medical Center |
Principal Investigator: | John McCann, MD | Baystate Medical Center |
Principal Investigator: | Walter A Kagan, MD PhD | Commonwealth Hematology/Oncology |
Study ID Numbers: | 7338 |
Study First Received: | August 10, 2005 |
Last Updated: | June 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00129974 |
Health Authority: | United States: Institutional Review Board |
Lung cancer Phase II Drug Therapy |
Thoracic Neoplasms Carcinoma, Neuroendocrine Carcinoma Neuroendocrine Tumors Folic Acid Pemetrexed Carcinoma, Small Cell Neuroectodermal Tumors |
Respiratory Tract Diseases Lung Neoplasms Neoplasms, Germ Cell and Embryonal Lung Diseases Neuroepithelioma Gemcitabine Adenocarcinoma Neoplasms, Glandular and Epithelial |
Antimetabolites Respiratory Tract Neoplasms Anti-Infective Agents Neoplasms by Histologic Type Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Neoplasms, Nerve Tissue |
Enzyme Inhibitors Folic Acid Antagonists Immunosuppressive Agents Antiviral Agents Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses |